What Muna Therapeutics does

Muna Therapeutics is a clinical-stage biotechnology company founded in 2020 and headquartered in Copenhagen, Denmark (with a US presence in Boston), developing orally administered small-molecule therapeutics for neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and Multiple Sclerosis. The company's strategy centres on enhancing brain resilience mechanisms — specifically by reprogramming disease-associated microglia through TREM2 agonism — rather than solely clearing pathology. Its lead asset, MNA-001, is a novel potent, selective, orally bioavailable small-molecule TREM2 agonist with best-in-class potential for early Alzheimer's disease; first subjects were dosed in a Phase 1 single-ascending dose / multiple-ascending dose study in November 2025, with topline data expected late summer 2026. A second program comprises small-molecule Kv1.3 potassium channel blockers targeting neuroinflammation in Parkinson's disease and Multiple Sclerosis (preclinical).

The discovery engine is the proprietary MiND-MAP platform (Microglia in NeuroDegeneration – Multi-Omics Analysis Platform), an all-in-human target identification system using single-cell spatial multi-omics and bioinformatics on unique patient tissue cohorts, validated externally in a June 2026 Nature Medicine publication with collaborators VIB, KU Leuven, and the UK Dementia Research Institute. Scientific founders include Bart De Strooper and Simon Glerup, and the company is led by CEO Rita Balice-Gordon and CSO Niels Plath.

Muna is privately held and pre-revenue from product sales. The business model is pharmaceutical R&D: capital comes from a $73M Series A (July 2021, co-led by Novo Holdings and Sofinnova Partners), non-dilutive grants from the Michael J. Fox Foundation ($4.9M, October 2022) and the Alzheimer's Association ($1M, January 2026), and a strategic licensing partnership with GSK worth up to $172.6M (announced June 2025) for neurodegeneration target identification. Once approvals are obtained, commercial revenues are expected to flow through traditional pharma channels (specialty pharmacy, hospital purchasing, physician prescribing) targeting neurologists and memory clinics.

Name

Muna Therapeutics

Legal name

Muna Therapeutics ApS

Website

https://munatherapeutics.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Muna Therapeutics is a clinical-stage biotech developing orally bioavailable small-molecule therapeutics that enhance brain resilience to treat Alzheimer's, Parkinson's, and Multiple Sclerosis, with lead asset MNA-001 (TREM2 agonist) in Phase 1 testing and discovery powered by its MiND-MAP multi-omics platform.

Ownership category

akta.pro rank

Product category

Neurodegenerative Disease Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF)

akta.pro secondary industries

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK)

Keywords

• Small molecule therapeutics
• Neurodegenerative disease treatment
• Alzheimer's drug development
• Parkinson's therapeutics
• Neuroscience drug discovery

Headquarters

HQ city

Copenhagen

HQ country

Denmark

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Development and Sales: Muna Therapeutics is developing small molecule drug candidates for neurodegenerative diseases. The company will generate revenue through the sale of approved therapeutics once clinical trials are successfully completed and regulatory approvals are obtained. The company is in Phase 1 clinical trials for lead asset MNA-001, with topline data expected mid-2026.

Go-to-market motion1 record

Marketing channels5 records

Core offering

Muna Therapeutics is a clinical-stage biotechnology company developing disease-modifying small molecule therapeutics for neurodegenerative diseases. Its lead asset, MNA-001, is an oral TREM2 agonist currently in Phase 1 clinical testing for early Alzheimer's disease. Earlier-stage pipeline includes Kv1.3 blockers for Parkinson's disease and Multiple Sclerosis. Drug discovery is powered by the proprietary MiND-MAP platform, which uses single-cell spatial multi-omics on patient brain tissue to identify targets linked to brain resilience.

Product overview

Muna Therapeutics is developing a portfolio of disease-modifying small molecule therapeutics for neurodegenerative diseases. The company's lead product is MNA-001, a TREM2 agonist currently in Phase 1 clinical testing for early Alzheimer's disease. The company's earlier-stage pipeline includes Kv1.3 blockers for Parkinson's disease and Multiple Sclerosis. These programs are supported by the MiND-MAP discovery platform, which uses human tissue samples and multi-omics analyses to identify and validate new therapeutic targets related to brain resilience mechanisms.

Differentiator

Problem solved

Functional benefit

Products and services

• MNA-001
• Kv1.3 Blockers
• MiND-MAP Platform

Quantifiable outcome

• MNA-001 demonstrated significant reduction in amyloid burden in mouse models of Alzheimer's-like pathology after three months of treatment
• +1 more outcomes

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

Partnerships

Four partnerships are on record, tiered core.

• GSKcoreStrategic or Co-development Partner · 30 June 2025GSK committed up to $950 million to acquire 35Pharma while also maintaining earlier-stage partnerships including a licensing deal with Muna Therapeutics worth up to $172.6 million as part of GSK's two-speed pipeline strategy combining broad early-stage partnerships with selective downstream acquisitions.
• VIB (Vlaams Instituut voor Biotechnologie)coreStrategic or Co-development PartnerCollaborated on seminal Nature Medicine publication identifying critical microglial state transitions as key drivers of Alzheimer's disease. VIB is a Belgian life sciences research institute.
• KU LeuvencoreStrategic or Co-development PartnerCollaborated on Nature Medicine study published June 2026 identifying critical transition in microglia that marks a tipping point between amyloid-beta plaque accumulation and tau pathology. KU Leuven is a leading Belgian university.
• UK Dementia Research Institute (UK-DRI)coreStrategic or Co-development PartnerCollaborating institution on the Nature Medicine study investigating microglial transitions and Alzheimer's disease resilience mechanisms.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Alector: Clinical-stage neuroscience biotech developing immune-modulating therapies for neurodegenerative diseases, with a lead TREM2-targeting program. Highly comparable to Muna given shared TREM2 biology focus and microglia-targeted approach in Alzheimer's.
• Vigil Neuroscience: Clinical-stage biotech developing TREM2-targeted therapeutics for rare and common neurodegenerative diseases. One of the most direct comparables given shared TREM2 agonist strategy and Alzheimer's focus.
• Denali Therapeutics: Clinical-stage biotech developing small molecule and biologic therapeutics for neurodegeneration, including microglia- and lysosomal-biology-targeted programs. Closely comparable platform-driven CNS biotech.
• Prothena: Clinical-stage biotech developing therapies for neurodegenerative diseases including Alzheimer's and Parkinson's. Comparable as a CNS-focused drug developer targeting protein-misfolding and neuroinflammation pathways.
• Athira Pharma: Clinical-stage biotech developing small molecule therapies for Alzheimer's and other neurodegenerative diseases. Comparable in modality, stage, and target indication focus.
• Cassava Sciences: Clinical-stage biotech developing small molecule therapies for Alzheimer's disease. Comparable as a small-molecule Alzheimer's developer, though with a different mechanistic approach.
• Anavex Life Sciences: Clinical-stage biotech developing small molecule therapies for Alzheimer's and other neurodegenerative diseases. Comparable in small molecule modality and CNS indication focus.

Broad incumbents

• Cerevel Therapeutics: Clinical-stage neuroscience company developing small molecule therapies for CNS disorders (acquired by AbbVie). Comparable in modality (small molecule) and CNS focus, with broader indication coverage.
• Sage Therapeutics: CNS-focused clinical-stage biotech (now Biogen partner) developing small molecule therapeutics for neurological disorders. Comparable in CNS small molecule focus and clinical stage.

Emerging players

• QurAlis: Clinical-stage biotech developing precision therapeutics for ALS and other neurodegenerative diseases, with shared investor Droia Ventures. Comparable as an emerging CNS biotech with shared European biotech ecosystem and pipeline-driven approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/muna-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds3 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Muna Therapeutics